ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development

European Journal of Cancer

Volumn 48, Issue 7, 2012, Pages 961-973

  Scagliotti, Giorgio ^a   Stahel, Rolf A ^b   Rosell, Rafael ^c   Thatcher, Nick ^d   Soria, Jean Charles ^e  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

ALK positive; Anaplastic lymphoma kinase translocation; Crizotinib; Molecular biomarkers; Molecular testing; Non small cell lung cancer; Oncogenic driver; Personalised medicine; Targeted agent; Trial design

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; PEMETREXED;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BALANCE DISORDER; BLURRED VISION; BURNING SENSATION; CHEILITIS; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG APPROVAL; DRUG TOLERABILITY; DYSESTHESIA; DYSGEUSIA; DYSPEPSIA; DYSPHAGIA; DYSPNEA; EDEMA; EPIGASTRIC BURNING; EPIGASTRIC DISCOMFORT; EPIGASTRIC PAIN; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS OBSTRUCTION; ESOPHAGUS PAIN; ESOPHAGUS SPASM; ESOPHAGUS ULCER; EYE DISEASE; FATIGUE; FEVER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GLOSSITIS; GLOSSODYNIA; HEADACHE; HUMAN; HYPERESTHESIA; HYPESTHESIA; INSOMNIA; LUNG NON SMALL CELL CANCER; MENTAL DISEASE; MOTOR NEUROPATHY; MOUTH PAIN; MOUTH ULCER; MUSCULOSKELETAL CHEST PAIN; MUSCULOSKELETAL DISEASE; NAUSEA; NEURALGIA; NEUROLOGIC DISEASE; NEUROPATHY; ODYNOPHAGIA; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PERSONALIZED MEDICINE; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; PRESYNCOPE; PRIORITY JOURNAL; RASH; REFLUX ESOPHAGITIS; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RHINOPHARYNGITIS; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; STOMATITIS; THORAX PAIN; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VITREOUS FLOATERS; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 84859508816     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.02.001     Document Type: Article

References (92)

1. E.L. Kwak, D.R. Camidge, and J. Clark Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 J Clin Oncol 27 2009 148s
2. E.L. Kwak, Y.J. Bang, and D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
3. Bang Y, Kway EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28 [Abstract 3].
4. Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(suppl.) [Abstract 2501].
5. Crin L, Kim D-W, Riely G, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011;29(suppl.) [Abstract 7514].
6. Pfizer Inc. Xalkori Prescribing Information. http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/202570s000lbl.pdf [last accessed 7 October 2011].
7. Blackhall FH, Petersen JA, Wilner K, et al. PROFILE 1005: preliminary patient-reported outcomes (PROs) from an ongoing phase 2 study of crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Oral presentation at the 14th World Conference on Lung Cancer (WCLC), Amsterdam, The Netherlands, July 3-7 2011 [Abstract 1510].
8. National Cancer Institute, National Human Genome Research Institute. The Cancer Genome Atlas. http://cancergenome.nih.gov/ [last accessed 22 August 2011].
9. I.B. Weinstein, and A. Joe Oncogene addiction Cancer Res 68 2008 3077 3080
10. T.A. Yap, S.K. Sandhu, P. Workman, and J.S. de Bono Envisioning the future of early anticancer drug development Nat Rev Cancer 10 2010 514 523
11. B.J. Druker, C.L. Sawyers, and H. Kantarjian Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 2001 1038 1042
12. G.D. Demetri, M. von Mehren, and C.D. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
13. M. Talpaz, N.P. Shah, and H. Kantarjian Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2006 2531 2541
14. M.S. Tsao, A. Sakurada, and J.C. Cutz Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
15. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
16. C. Zhou, Y.L. Wu, and G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
17. F.A. Shepherd Molecular selection trumps clinical selection J Clin Oncol 29 2011 2843 2844
18. New York Times. New Drugs Stir Debate on Rules of Clinical Trials. http://www.nytimes.com/2010/09/19/health/research/19trial.html [last accessed 19 August 2011].
19. R. Dagher, M. Cohen, and G. Williams Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors Clin Cancer Res 8 2002 3034 3038
20. C.D. Blanke, C. Rankin, and G.D. Demetri Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 2008 626 632
21. D.E. Gerber, and J.D. Minna ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time Cancer Cell 18 2010 548 551
22. G. Bronte, S. Rizzo, and L. La Paglia Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma Cancer Treat Rev 36 suppl. 3 2010 S21 S29
23. K. Garber ALK, lung cancer, and personalized therapy: portent of the future? J Natl Cancer Inst 102 2010 672 675
24. F. Janku, D.J. Stewart, and R. Kurzrock Targeted therapy in non-small-cell lung cancer - is it becoming a reality? Nat Rev Clin Oncol 7 2010 401 414
25. M. Fukuoka, Y.L. Wu, and S. Thongprasert Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2011 2866 2874
26. F.A. Shepherd, P.J. Rodrigues, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
27. N. Thatcher, A. Chang, and P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
28. S.W. Morris, M.N. Kirstein, and M.B. Valentine Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma Science 263 1994 1281 1284
29. M. Shiota, S. Nakamura, and R. Ichinohasama Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity Blood 86 1995 1954 1960
30. D. Bischof, K. Pulford, D.Y. Mason, and S.W. Morris Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis Mol Cell Biol 17 1997 2312 2325
31. M. Shiota, and S. Mori The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK Leuk Lymphoma 23 1996 25 32
32. E. Lin, L. Li, and Y. Guan Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers Mol Cancer Res 7 2009 1466 1476
33. R.H. Palmer, E. Vernersson, C. Grabbe, and B. Hallberg Anaplastic lymphoma kinase: signalling in development and disease Biochem J 420 2009 345 361
34. K. Pulford, S.W. Morris, and F. Turturro Anaplastic lymphoma kinase proteins in growth control and cancer J Cell Physiol 199 2004 330 358
35. R.E. George, T. Sanda, and M. Hanna Activating mutations in ALK provide a therapeutic target in neuroblastoma Nature 455 2008 975 978
36. Y.P. Mosse, M. Laudenslager, and L. Longo Identification of ALK as a major familial neuroblastoma predisposition gene Nature 455 2008 930 935
37. R. Chiarle, C. Voena, and C. Ambrogio The anaplastic lymphoma kinase in the pathogenesis of cancer Nat Rev Cancer 8 2008 11 23
38. M. Soda, Y.L. Choi, and M. Enomoto Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
39. M. Soda, S. Takada, and K. Takeuchi A mouse model for EML4-ALK-positive lung cancer Proc Natl Acad Sci U S A 105 2008 19893 19897
40. A.T. Shaw, B.Y. Yeap, and M. Mino-Kenudson Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
41. T. Sasaki, S.J. Rodig, L.R. Chirieac, and P.A. Janne The biology and treatment of EML4-ALK non-small cell lung cancer Eur J Cancer 46 2010 1773 1780
42. S.J. Rodig, M. Mino-Kenudson, and S. Dacic Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population Clin Cancer Res 15 2009 5216 5223
43. D.W. Wong, E.L. Leung, and K.K. So The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS Cancer 115 2009 1723 1733
44. T. Takahashi, M. Sonobe, and M. Kobayashi Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene Ann Surg Oncol 17 2010 889 897
45. X. Zhang, S. Zhang, and X. Yang Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression Mol Cancer 9 2010 188
46. J.M. Boland, S. Erdogan, and G. Vasmatzis Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas Hum Pathol 40 2009 1152 1158
47. L. Horn, and W. Pao EML4-ALK: honing in on a new target in non-small-cell lung cancer J Clin Oncol 27 2009 4232 4235
48. T. Sasaki, and P.A. Janne New strategies for treatment of ALK rearranged non-small cell lung cancers Clin Cancer Res 17 2011 7213 7218
49. D.R. Camidge, M. Theodoro, and D.A. Maxson The percentage of tumor cells showing an ALK rearrangement in ALK FISH positive lung cancer correlates with signal copy number, but not with response to crizotinib therapy J Thorac Oncol 6 2011 S508
50. US Food and Drug Administration (FDA). Vysis ALK Break Apart FISH Probe Kit. http://www.accessdata.fda.gov/cdrh-docs/pdf11/p110012a.pdf [last accessed 21 October 2011].
51. D.R. Camidge, F.R. Hirsch, M. Varella-Garcia, and W.A. Franklin Finding ALK-positive lung cancer: what are we really looking for? J Thorac Oncol 6 2011 411 413
52. J.K. Lee, H.S. Park, and D.-W. Kim Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients J Thorac Oncol 6 2011 S294
53. J.H. Paik, G. Choe, and H. Kim Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization J Thorac Oncol 6 2011 466 472
54. Wallander ML, Geiersbach KB, Tripp S, Layfield LJ. Comparison of IHC, FISH and RT-PCR for the detection of EML4-ALK translocation variants in non-small cell lung cancer. Poster presented at the 100th Annual Meeting of the United States and Canadian Academy of Pathology (USCAP), San Antonio, TX, USA, 26 February-4 March 2011.
55. E.S. Yi, J.M. Boland, and J.J. Maleszewski Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH J Thorac Oncol 6 2011 459 465
56. K. Rikova, A. Guo, and Q. Zeng Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203
57. J.P. Koivunen, C. Mermel, and K. Zejnullahu EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin Cancer Res 14 2008 4275 4283
58. K. Inamura, K. Takeuchi, and Y. Togashi EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers J Thorac Oncol 3 2008 13 17
59. K. Takeuchi, Y.L. Choi, and M. Soda Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts Clin Cancer Res 14 2008 6618 6624
60. S. Perner, P.L. Wagner, and F. Demichelis EML4-ALK fusion lung cancer: a rare acquired event Neoplasia 10 2008 298 302
61. K. Shinmura, S. Kageyama, and H. Tao EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas Lung Cancer 61 2008 163 169
62. M.P. Martelli, G. Sozzi, and L. Hernandez EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues Am J Pathol 174 2009 661 670
63. P.K. Paik, M.E. Arcila, and M. Fara Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations J Clin Oncol 29 2011 2046 2051
64. Kulig K, Yang P. Predictive and prognostic value of ALK rearrangement in non-small cell lung cancer. Ann Oncol 2011 (submitted manuscript).
65. Kim DW, Lee J, Park HS, et al. Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors. J Clin Oncol 2011;29(suppl.) [Abstract 7515].
66. Yang P, Kulig K. Anaplastic lymphoma kinase status and clinical outcomes by IHC and FISH: A retrospective study of never-smoker, adenocarcinoma lung cancer cases. Poster presentation at EMCTO 2011 (Abstract 47PD).
67. A.T. Shaw, B.Y. Yeap, and B.J. Solomon Effect of crizotinib on overall survival in advanced NSCLC harboring anaplastic lymphoma kinase gene rearrangement: a retrospective analysis Lancet Oncol 12 2011 1004 1012
68. J.G. Christensen, H.Y. Zou, and M.E. Arango Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol Cancer Ther 6 2007 3314 3322
69. M. Zillhardt, J.G. Christensen, and E. Lengyel An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis Neoplasia 12 2010 1 10
70. H.Y. Zou, Q. Li, and J.H. Lee An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res 67 2007 4408 4417
71. Camidge DR, Bang Y, Iafrate AJ, et al. Clinical activity of crizotinib (PF-02341066), in ALK-positive patients with non-small cell lung cancer (NSCLC). Ann Oncol 2010;21:viii122.
72. Y. Tang, B. Huang, K.D. Wilner, and P. Selaru Efficacy of crizotinib in retrospective comparisons with standard-of-care regimens (SOC) regimens from three Pfizer-sponsored clinical trials in patients with advanced non-small cell lung cancer (NSCLC) J Thorac Oncol 6 2011 S1231
73. D.R. Camidge, S.A. Kono, and X. Lu Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed J Thorac Oncol 6 2011 774 780
74. J.O. Lee, T.M. Kim, and S.H. Lee Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer J Thorac Oncol 6 2011 1474 1480
75. Altavilla G, Santarpia M, Arrigo C, et al. EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. J Clin Oncol 2010;28(suppl.) [Abstract 7610].
76. Solomon B, Chiappori A, Lamb A, et al. Preliminary characterization of visual events reported by patients receiving crizotinib for the treatment of advanced ALK-positive non-small cell lung cancer. Poster presented at the 2011 European Multidisciplinary Cancer Congress, Stockholm, Sweden, 23-27 September 2011 [Abstract 3030].
77. G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
78. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
79. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
80. G.V. Scagliotti, F. De Marinis, and M. Rinaldi Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 2002 4285 4291
81. C.G. Azzoli, S. Temin, and T. Aliff Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-small-cell Lung Cancer J Clin Oncol 29 2011 3825 3831
82. J.M. Peppercorn, T.J. Smith, and P.R. Helft American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer J Clin Oncol 29 2011 755 760
83. Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 Reference Values. http://www.google.co.uk/search?q= Scott+NW+Reference+Values+Manual+Quality+of+Life+Group+Publications+2008& btnG=Search&hl=en [last accessed 19 August 2011].
84. R.S. Herbst, D. Prager, and R. Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
85. U. Gatzemeier, A. Pluzanska, and A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial J Clin Oncol 25 2007 1545 1552
86. G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 2004 777 784
87. R.S. Herbst, G. Giaccone, and J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794
88. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
89. K.T. Flaherty, I. Puzanov, and K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
90. A.T. Shaw, D.G. Forcione, S.R. Digumarthy, and A.J. Iafrate Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung N Engl J Med 365 2011 158 167
91. Wagstaff A. Dying for a lack of compassion? http://www.cancerworld.org/ pdf/6116-drugwatch.pdf [last accessed 22 August 2011].
92. F. Andre, S. Delaloge, and J.C. Soria Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 29 2011 1236 1238